These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 26026587)
1. The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors. Cetin B; Gonul II; Buyukberber S; Afsar B; Gumusay O; Algın E; Turan N; Ozet A; Benekli M; Coskun U Tumour Biol; 2015 Nov; 36(11):8471-8. PubMed ID: 26026587 [TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in patients with advanced renal cell carcinoma. Muriel López C; Esteban E; Berros JP; Pardo P; Astudillo A; Izquierdo M; Crespo G; Sanmamed M; Fonseca PJ; Martínez-Camblor P Clin Genitourin Cancer; 2012 Dec; 10(4):262-70. PubMed ID: 22959659 [TBL] [Abstract][Full Text] [Related]
3. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759 [TBL] [Abstract][Full Text] [Related]
4. Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Park I; Cho YM; Lee JL; Ahn JH; Lee DH Tumour Biol; 2016 Apr; 37(4):4919-27. PubMed ID: 26526582 [TBL] [Abstract][Full Text] [Related]
5. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Driessen A; Landuyt W; Pastorekova S; Moons J; Goethals L; Haustermans K; Nafteux P; Penninckx F; Geboes K; Lerut T; Ectors N Ann Surg; 2006 Mar; 243(3):334-40. PubMed ID: 16495697 [TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme. Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031 [TBL] [Abstract][Full Text] [Related]
7. Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. Kim HS; Kim WS; Park SH; Jung CW; Choi HY; Lee HM; Jeon SS; Ha H; Hwang IG; Lee S; Lim HY Urol Oncol; 2010; 28(2):157-63. PubMed ID: 18976937 [TBL] [Abstract][Full Text] [Related]
8. Identification and validation of novel prognostic markers in Renal Cell Carcinoma. Rabjerg M Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890 [TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453 [TBL] [Abstract][Full Text] [Related]
10. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979 [TBL] [Abstract][Full Text] [Related]
11. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Hui EP; Chan AT; Pezzella F; Turley H; To KF; Poon TC; Zee B; Mo F; Teo PM; Huang DP; Gatter KC; Johnson PJ; Harris AL Clin Cancer Res; 2002 Aug; 8(8):2595-604. PubMed ID: 12171890 [TBL] [Abstract][Full Text] [Related]
12. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780 [TBL] [Abstract][Full Text] [Related]
13. Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma. Papworth K; Sandlund J; Grankvist K; Ljungberg B; Rasmuson T Anticancer Res; 2010 Jul; 30(7):2953-7. PubMed ID: 20683038 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876 [TBL] [Abstract][Full Text] [Related]
15. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib. Cetin B; Gonul II; Gumusay O; Afsar B; Bilgetekin I; Ozet A; Uner A J Cancer Res Ther; 2021; 17(2):408-413. PubMed ID: 34121685 [TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. Sandlund J; Oosterwijk E; Grankvist K; Oosterwijk-Wakka J; Ljungberg B; Rasmuson T BJU Int; 2007 Sep; 100(3):556-60. PubMed ID: 17608827 [TBL] [Abstract][Full Text] [Related]
17. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Hussain SA; Ganesan R; Reynolds G; Gross L; Stevens A; Pastorek J; Murray PG; Perunovic B; Anwar MS; Billingham L; James ND; Spooner D; Poole CJ; Rea DW; Palmer DH Br J Cancer; 2007 Jan; 96(1):104-9. PubMed ID: 17213826 [TBL] [Abstract][Full Text] [Related]